1. Home
  2. DYN vs AACT Comparison

DYN vs AACT Comparison

Compare DYN & AACT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DYN
  • AACT
  • Stock Information
  • Founded
  • DYN 1984
  • AACT 2021
  • Country
  • DYN United States
  • AACT United States
  • Employees
  • DYN N/A
  • AACT N/A
  • Industry
  • DYN Medicinal Chemicals and Botanical Products
  • AACT
  • Sector
  • DYN Health Care
  • AACT
  • Exchange
  • DYN Nasdaq
  • AACT Nasdaq
  • Market Cap
  • DYN 848.8M
  • AACT 697.5M
  • IPO Year
  • DYN 2020
  • AACT 2023
  • Fundamental
  • Price
  • DYN $10.78
  • AACT $11.24
  • Analyst Decision
  • DYN Strong Buy
  • AACT
  • Analyst Count
  • DYN 12
  • AACT 0
  • Target Price
  • DYN $47.73
  • AACT N/A
  • AVG Volume (30 Days)
  • DYN 2.8M
  • AACT 1.4M
  • Earning Date
  • DYN 05-05-2025
  • AACT 01-01-0001
  • Dividend Yield
  • DYN N/A
  • AACT N/A
  • EPS Growth
  • DYN N/A
  • AACT 15.24
  • EPS
  • DYN N/A
  • AACT 0.42
  • Revenue
  • DYN N/A
  • AACT N/A
  • Revenue This Year
  • DYN N/A
  • AACT N/A
  • Revenue Next Year
  • DYN N/A
  • AACT N/A
  • P/E Ratio
  • DYN N/A
  • AACT $27.01
  • Revenue Growth
  • DYN N/A
  • AACT N/A
  • 52 Week Low
  • DYN $6.36
  • AACT $10.58
  • 52 Week High
  • DYN $47.45
  • AACT $11.24
  • Technical
  • Relative Strength Index (RSI)
  • DYN 57.30
  • AACT 66.58
  • Support Level
  • DYN $7.38
  • AACT $11.15
  • Resistance Level
  • DYN $8.01
  • AACT $11.22
  • Average True Range (ATR)
  • DYN 0.91
  • AACT 0.03
  • MACD
  • DYN 0.44
  • AACT 0.00
  • Stochastic Oscillator
  • DYN 92.47
  • AACT 95.45

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

About AACT Ares Acquisition Corporation II

Ares Acquisition Corp II is a blank check company.

Share on Social Networks: